1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,710 | 0,820 | 15:30 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Arecor Therapeutics - Result of AGM | - | RNS | ||
| 21.05. | Arecor Therapeutics grants 455,000 stock options to executives | 1 | Investing.com | ||
| 21.05. | Arecor Therapeutics - Grant of options and PDMR dealing | - | RNS | ||
| ARECOR THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.05. | Arecor Therapeutics - Upcoming conference attendance | - | RNS | ||
| 28.04. | Arecor Therapeutics - Posting of Annual Report and Notice of AGMm | - | RNS | ||
| 13.04. | Arecor Therapeutics swings to annual profit; hails insulin product | 4 | Alliance News | ||
| 13.04. | Arecor Therapeutics - Final Results | 3 | RNS | ||
| 30.03. | Arecor Therapeutics - Notice of FY25 Results | - | RNS | ||
| 26.03. | Arecor erhält Meilensteinzahlung von 0,5 Mio. US-Dollar aus Vereinbarung mit Ligand | 1 | Investing.com Deutsch | ||
| 26.03. | Arecor receives $0.5m milestone from Ligand deal | 1 | Investing.com | ||
| 26.03. | Arecor Therapeutics - Ligand Pharmaceuticals Milestone Payment | - | RNS | ||
| 09.03. | Arecor Therapeutics - Arecor to present at Oppenheimer conference | - | RNS | ||
| 09.02. | Arecor Therapeutics revenue falls after Tetris Pharma operations cease | 1 | Alliance News | ||
| 09.02. | Arecor's ultra-concentrated insulin advances with Sequel partnership | 2 | Investing.com | ||
| 09.02. | Arecor treibt ultrakonzentriertes Insulin durch Partnerschaft mit Sequel voran | 1 | Investing.com Deutsch | ||
| 09.02. | Arecor Therapeutics - 2025 Business Update | - | RNS | ||
| 06.01. | Arecor Therapeutics - Fireside Panel Discussion on Diabetes sector | - | RNS | ||
| 09.12.25 | Arecor, Sequel Med Tech to host virtual panel on diabetes care | 2 | Investing.com | ||
| 09.12.25 | Arecor Therapeutics - Arecor and Sequel Med Tech to host fireside panel | - | RNS | ||
| 25.09.25 | Arecor Therapeutics PLC: Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292 | 191 | GlobeNewswire (Europe) | This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc("Arecor" or the "Company")... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 15,710 | 0,00 % | Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments | ||
| ERASCA | 13,820 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,790 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| EDGEWISE THERAPEUTICS | 40,290 | +0,07 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,820 | +0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,100 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| TYRA BIOSCIENCES | 30,390 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| IMMUNOME | 20,780 | 0,00 % | Immunome: Phase-3-Studie zu Varegacestat zeigt hohe Wirksamkeit bei Desmoid-Tumoren | ||
| IMMUNOVANT | 32,830 | -0,09 % | H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data | ||
| INHIBRX BIOSCIENCES | 99,29 | 0,00 % | Stifel reiterates Inhibrx Biosciences stock rating on durability data | ||
| JADE BIOSCIENCES | 18,625 | +0,19 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 37,510 | 0,00 % | Mizuho erhöht Kursziel für Enliven Therapeutics im Vorfeld von Studiendaten | ||
| BEAM THERAPEUTICS | 31,140 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| CG ONCOLOGY | 59,25 | +0,03 % | CG Oncology, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 335,12 | -0,01 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen |
Das Unternehmen ARECOR THERAPEUTICS PLC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,645 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARECOR THERAPEUTICS PLC finden Sie auf Wallstreet Online.